Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
Condition: Hepatocellular Carcinoma Interventions: Drug: Sorafenib; Procedure: Transarterial chemoembolization Sponsor: Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials